AI assistant
TISSUE REGENIX GROUP PLC — Management Reports 2017
Mar 13, 2017
7973_rns_2017-03-13_c30297a5-b6f4-4e15-bc98-e005f3fbcdd4.html
Management Reports
Open in viewerOpens in your device viewer
National Storage Mechanism | Additional information
You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.
RNS Number : 1719Z
Tissue Regenix Group PLC
13 March 2017
Hardman Research: Addressing woundcare in the US
Addressing woundcare in the US: TRX has a broad portfolio of regenerative medicine products developed from decellularised human and porcine tissues for the wound care, orthopaedics, and cardiac markets. Sales of DermaPure have continued to gain traction in the US following launch in 2014 - growth in 1H 2016 was +128%. Since launch, the focus has been on expanding Medicare coverage, but recent news has been about increasing access into both in- and out-patient populations through GPOs and the Veterans Association. This further strengthens DermaPure's commercial position, in line with the company's strategy, and underpins our forecasts for fiscal 2017.
Please click here for the full report:
| To contact us: Hardman & Co 11/12 Tokenhouse Yard London EC2R 7AS |
Contacts: Dr Martin Hall [email protected] Dr Dorothea Hill [email protected] Dr Gregoire Pave [email protected] Telephone: +44 20 7929 3399 Follow us on Twitter @HardmanandCo |
www.hardmanandco.com
About Hardman & Co: For the past 20 years Hardman has been producing specialist research designed to improve investors' understanding of companies, sectors, industries and investment securities. Our analysts are highly experienced in their sectors, and have often been highly rated by professional investors for their knowledge. Our focus is to raise companies' profiles across the UK and abroad with outstanding research, investor engagement programmes and advisory services. Some of our notes have been commissioned by the company which is the subject of the note; this is clearly stated in the disclaimer where this is the case.
Hardman Research Ltd, trading as Hardman & Co, is an appointed representative of Capital Markets Strategy Ltd and is authorised and regulated by the Financial Conduct Authority; our FCA registration number is 600843. Hardman Research Ltd is registered at Companies House with number 8256259.
Our research is provided for the use of the professional investment community, market counterparties and sophisticated and high net worth investors as defined in the rules of the regulatory bodies. It is not intended to be made available to unsophisticated retail investors. Anyone who is unsure of their categorisation should consult their professional advisors. This research is neither an offer, nor a solicitation, to buy or sell any security. Please read the note for the full disclaimer.
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRAGGUCCWUPMGPU